Guardian Pharmacy Services Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
13.7%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
$1.30next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 9 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Residents Served Quarterly207K
Adjusted EBITDA Quarterly29.8MTarget: 123000000 - 127000000
Revenue Quarterly336.6MTarget: 1400000000 - 1420000000
Watch Items
- Inflation Reduction Act (IRA) Branded Drug Pricing HeadwindsTrigger: Gross profit headwind exceeding $10 million without mitigationAction: Accelerate payor negotiations, optimize drug mix, and implement process changes to offset margin compression.
- M&A Pipeline and Integration ExecutionTrigger: Acquisition margin drag persisting beyond 3-4 years post-dealAction: Deploy proprietary technology platforms (Guardian Compass) to drive operational efficiencies and scale acquired pharmacies to corporate average margins.
Research as of 20 Jun 2026